Nutriband Inc. (OTC: NTRB)  - Breaking News - April 10, 2018
 

NUTRIBAND INC. ACQUIRES 4P THERAPEUTICS INC.

Orlando, Fla. – April 10, 2018 – Nutriband Inc. (OTC: NTRB), a Nevada Corporation, is pleased to announce the acquisition of 4P Therapeutics Inc. on April 5, 2018.

Nutriband has acquired 100% interest in 4P Therapeutics for a total of $1,900,000 payable in both company stock and cash. 4P Therapeutics will receive 250,000 shares of common stock and a cash amount of $400,000. Steven Damon, CEO of 4P Therapeutics, has been appointed to the Nutriband Inc. Board of Directors.

4P Therapeutics will now become the Pharmaceutical and Development arm of Nutriband Inc. with a specific focus on Transdermal and Topical Technologies, prescription drugs and clinical development.

Included in the acquisition of 4P’s IP Portfolio is Defent™ abuse deterrent patch technology, an opioid abuse deterrent platform for the transdermal delivery of opioid-based medications. Defent™ lowers the risk of abuse and misuse, creating a safer treatment for patients.

Nutriband has also acquired 4P’s Exenatide transdermal delivery system, currently in Phase I clinical development. If successfully taken through Phase III and to commercialization, it will compete with injectable Exenatide such as Byetta® and Bydureon® by providing an injection free alternative for patients with type II diabetes.

A Full Pipeline of drugs and technology can be found on 4P’s website http://www.4ptherapeutics.com/.

4P Therapeutics is a private company focused on the research and development of novel drug delivery technologies and therapeutics. 4P develops products that meet the needs of patients, physicians and payers. The company has capabilities for developing pharmaceutical products ranging from pre-clinical testing to clinical manufacturing and early stage clinical development (Phase I/II). A key company focus and area of expertise is in the development of transdermal products for currently injected compounds, including proteins, peptides, macromolecules and biologics. Transdermal delivery of commercially available drugs or biologics that are typically delivered via injection has the potential to improve safety, efficacy and therapeutic outcomes associated with these treatments.

Nutriband Inc. appointed Steven Damon to its Board of Directors. Steven Damon has over 30 years of experience with various business roles in the medical and pharmaceutical industries. As well as founding 4P Therapeutics, Steven also maintains an executive leadership role as Vice President for Business and Commercial Development with Femasys an Atlanta based women’s health care medtech company. In addition, he serves on the boards of Micron Biomedical, Carmel Bioscience, Temple Therapeutics and Georgia BIO. He actively consults with various companies on strategy, financing and M&A.

Before founding 4P Therapeutics, Steven led the Business Development team at Atlanta based Altea Therapeutics as the company's Senior Vice President of Business Development. He founded and was President of Absorbable Polymers International a Birmingham, Alabama company. He was an Executive Director at DURECT Corporation in Cupertino California where he led Business Development activities and was responsible for the ALZET research drug delivery pump business. Steve started his life science career with Kimberly-Clark Healthcare (now Halyard Healthcare) with lead responsibilities for commercial development of the healthcare business in Europe and the acquisitions of a number of life science companies and products.

Additional activities include industry related speaking engagements, publications and committee participation. Steven has been a long time mentor for the Emory and Georgia Tech Ti:GER program and also participates in other GT student mentoring programs.

Nutriband Inc. appointed Alan Smith Ph.D. as Head of Regulatory and Clinical Operations. Alan Smith, Ph.D., co-founded 4P Therapeutics in 2011 and serves as Vice President, Clinical, Regulatory, Quality, and Operations. Previously, he was with Altea Therapeutics, most recently serving as Vice President, Product Development and Head of Clinical R&D, Regulatory Affairs, and Project Management. At Altea, he led major research and development programs with pharmaceutical companies such as Eli Lilly, Amylin, Hospira, Elan, and Novartis. He joined Altea as one of the first employees and spent 12 years growing its multidisciplinary drug delivery research and development organization.

Dr. Smith has 20 years of experience in the research and development of drug and biologic delivery systems, diagnostics and medical devices for treatment and management of diabetes, chronic pain and cardiovascular disease. Prior to joining Altea Therapeutics, he led the development of transdermal glucose monitoring systems at SpectRx, Inc., a publicly traded noninvasive diagnostics company. Dr. Smith received Ph.D. and M.S. degrees in Biomedical Engineering from Rutgers University and the University of Medicine and Dentistry of New Jersey. He currently serves on the Editorial Advisory Board of Expert Opinion on Drug Delivery.

Nutriband Inc.
Nutriband is a unique, result’s driven, health and pharmaceutical Company based in Orlando Florida. Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.

About Our Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words “believes”, “anticipates”, “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. Our actual results may differ materially from those anticipated in our forward-looking statements as a result of a number of factors, including our ability to create, sustain, manage or forecast our growth; our ability to attract and retain key personnel; changes in our business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions. Except as required by applicable law, we undertake no obligation to revise or update any of our forward-looking statements in order to reflect any event or circumstance that may arise after the date hereof.

For more information, contact:
Gareth Sheridan
CEO
Nutriband Inc.
407-880-6810
info@nutriband.com
www.nutriband.com

SOURCE Nutriband Inc.

Nutriband Inc. Granted Official Trademark on 'Nutriband' Logo and Wordmark by USPTO

Orlando, Fla. – March 1, 2018 – Nutriband Inc. (OTC: NTRB), a Nevada Corporation, is pleased to announce that it has received a certificate of registration for the 'NUTRIBAND' Trademark and 'NUTRIBAND' Wordmark by the U.S Patent and Trademark office.

The details of the registration are as follows
Trademark Registration Number: 5,330,456
Wordmark Registration Number: 5,330,455

Details of both certificates can be found at the following links respectively
Trademark:
http://tsdr.uspto.gov/documentviewer?caseId=sn86926678&docId=ORC20171022090221#docIndex=0&page=1 
Wordmark:
http://tsdr.uspto.gov/documentviewer?caseId=sn86926667&docId=ORC20171022090218#docIndex=0&page=1

About Nutriband Inc.

Nutriband is a unique, result's driven, health and pharmaceutical Company based in Orlando Florida. Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.
www.nutriband.com – Corporate
www.shopnutriband.com – Find a list of our products available for purchase

About Our Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words "believes", "anticipates", "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. Our actual results may differ materially from those anticipated in our forward-looking statements as a result of a number of factors, including our ability to create, sustain, manage or forecast our growth; our ability to attract and retain key personnel; changes in our business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions. Except as required by applicable law, we undertake no obligation to revise or update any of our forward-looking statements in order to reflect any event or circumstance that may arise after the date hereof.

For more information, contact:
Gareth Sheridan
CEO
Nutriband Inc.
407 880-6810
191187@email4pr.com
www.nutriband.com

https://c212.net/c/img/favicon.png?sn=PH27244&sd=2018-03-01 View original content with multimedia:http://www.prnewswire.com/news-releases/nutriband-inc-granted-official-trademark-on-nutriband-logo-and-wordmark-by-uspto-300606442.html

SOURCE Nutriband Inc.

Nutriband Inc. Appoints Sean Gallagher As Company President

Orlando, Fla. – Feb. 13, 2018 – Nutriband Inc. (OTC: NTRB), a Nevada Corporation, today announced the appointment of Sean Gallagher as company President and to the Board of Directors.

Presidential candidate and runner up in the 2011 Irish presidential election, Sean Gallagher is an experienced businessman, inspiring speaker, and highly regarded business writer. Gallaher's notable business ventures include co-founding and serving as CEO of Clyde Real Estate, Pharmaceutical Directorships, and co-founding Ireland's largest home technology company, Smarthomes. Gallagher has also served as an investor on the popular TV show Dragon's Den, Ireland and UK's version of Shark Tank.

Gallagher qualified with an MBA from the University of Ulster and served on a number of Irish State Boards including the National Training and Employment Agency (FAS), the North South Trade Body (InterTrade Ireland), and was Chair of the state-owned Drogheda Port Company.

About Nutriband Inc.

Nutriband is a unique, results driven, health and pharmaceutical Company based in Orlando, Florida. Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.
www.nutriband.com

About Our Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words "believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. Our actual results may differ materially from those anticipated in our forward-looking statements as a result of a number of factors, including our ability to create, sustain, manage or forecast our growth; our ability to attract and retain key personnel; changes in our business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions. Except as required by applicable law, we undertake no obligation to revise or update any of our forward-looking statements in order to reflect any event or circumstance that may arise after the date hereof.

For more information, contact:
Gareth Sheridan
CEO
Nutriband Inc.
407-880-6810
190294@email4pr.com
www.nutriband.com

https://c212.net/c/img/favicon.png?sn=PH12600&sd=2018-02-13 View original content with multimedia:http://www.prnewswire.com/news-releases/nutriband-inc-appoints-sean-gallagher-as-company-president-300597349.html

SOURCE Nutriband Inc.

-------------------------------------------------------------------
About Nutriband Inc.:

Good health is important to all of us, and finding solutions and maintaining technological advances in the area of health care is vital to achieving this.

Nutriband products are on the cutting edge of scientific research to meet the needs of our customers through a unique and simple way; A scientifically formulated dermal patch!

Our products are designed on the principle that molecular combinations can be absorbed not only orally but also, through the skin.

Transdermal (taking through the skin) technology is not only becoming more and more mainstream in the medicine industry because of its many benefits, it is also the way forward for the Nutriceutical industry.

Because of the method of intake, all Nutriband products contain nothing but the bare essential ingredients as there are no need for binders, fillers or unwanted animal by-products such as gelatine.

Nutriband Life Sciences is the pharmaceutical division of Nutriband Inc. focused on the development, research and marketing of innovative drug delivery systems.

We consistently evaluate our operations and progressions and on listening to the views of all of the people involved in health care decisions such as the FDA and Medical Journals. and our R&D partner’s.

Through working in partnership with everyone from Research partners to Manufacturers our goal is to ensure that people everywhere will have access to innovative treatments, technological advances and quality health care.

Our Mission
To be the leader in Global Transdermal Research and Drug Development
To provide alternative treatments using TD technology
To better the lives of patients

Drug Development
Our Drug Pipeline // Currently in formulation, feasibility and pre-clinical evaluation

Cardiovascular Disease
TD0CD1 // TD0CD2

Infectious Disease
TD0ID1

Gastrointestinal
TD00G1

Inflammatory Joint Disease
TD0IJD1

Allergy/Asthma
TD00A1

Diabetes
TD00G1

Research
Learn how we do our research

Imagine a world with improved patient compliance, a more steady drug delivery state, less frequent dosing, minimal adverse effects, is less invasive and fewer problems with gastrointestinal absorption issues, all of which are avoided by eliminating first pass metabolism.

Transdermal Drug Delivery Systems

— A Simple, Convenient Way to Get the Remedy You Need —

While tablets and injections have been the traditional way to take remedies and medications, new options are becoming increasingly popular.

One highly successful alternative delivery method is the transdermal or “through the skin” patch.

Patches can offer several benefits, including more consistent symptom control, enhanced convenience, increased tolerability and the potential for fewer side effects.

Transdermal Delivery System Advantages:
Enhancing bioavailability through bypassing first pass metabolism

Minimizing pharmaco-kinetic peaks and troughs

Improving tolerability and dosing

Increasing patient compliance

Continuous delivery

Factors that can affect bioavailability: the size and type of pill/capsule, the type of inert ingredients included in the preparation, and the crystalline properties and rates of dissolution of the drug itself.

While most prescription, over-the-counter and dietary supplement pills, capsules, or powder formulas may be good, they simply cannot get most of their formula nutrients into your bloodstream, which is where they must go to deliver the benefits and results you want.

With today’s advanced time-release transdermal patches, virtually 100% of the formula’s dosages levels are delivered directly into your bloodstream, with no degrading stops along the way (stomach Acids & liver). Better yet, with time-release patches, a person’s system can metabolize the formula nutrients more efficiently.

Nutriband products are on the cutting edge of scientific research to meet the needs of our customers through a unique and simple way; A scientifically formulated dermal patch!

Our products are designed on the principle that molecular combinations can be absorbed not only orally but also, through the skin.

Transdermal (taking through the skin) technology is not only becoming more and more mainstream in the medicine industry because of its many benefits, it is also the way forward for the Nutriceutical industry.

Because of the method of intake, all Nutriband products contain nothing but the bare essential ingredients as there are no need for binders, fillers or unwanted animal by-products such as gelatine.

For further investment information please contact us at investorrelations@nutriband.com 

SOURCE: http://nutriband.com/

Disclaimer